Circulating Ceramide 16:0 in Heart Failure With Preserved Ejection Fraction

Ceramides are a class of bioactive sphingolipids increasingly recognized in metabolic disease, heart failure (HF), atherosclerosis, and cardiovascular death ([1][1]). Despite accumulating evidence linking ceramides to HF risk, little is known about circulating ceramides and clinical outcomes in HF